RTTNews | Sep 10, 2021 09:22AM EDT

09:21 Friday, September 10, 2021 (RTTNews.com) - AzurRx BioPharma Inc. (AZRX) said that it has activated seven new clinical trial sites in India for phase 2 RESERVOIR Trial evaluating niclosamide for the treatment of COVID-19 gastrointestinal infections.

The phase 2 placebo-controlled clinical trial will confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract.

The seven new clinical trial sites in India, together with the existing eleven sites in the U.S. and the five trial sites recently added in the Ukraine, brings the total number of RESERVOIR trial sites to twenty-three. AzurRx expects to report topline results during the first quarter of 2022.

The long-term observation data could indicate that niclosamide treatment has the potential to improve "long haul" COVID-19 symptoms. FW-1022 is a niclosamide based small molecule drug which the Company's clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections. FW-1022 is anticipated to be supplied as an oral immediate release tablet.

On Thursday, AzurRx BioPharma said that an independent data monitoring committee or DMC approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

Read the original article on RTTNews ( https://www.rttnews.com/3224834/azurrx-activates-new-clinical-trial-sites-in-india-for-gastrointestinal-infections-covid-19-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved